Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
36 drugs in development
By Therapeutic Area
top 4
R&D Momentum
97/100
Pipeline Velocity
83/100
Trial Completion Rate
87/100
Pipeline Concentration
64/100
Pipeline Freshness
61/100
Strategic Signals
Activity
Last 14 days
Efficacy and Safety of Dalpiciclib Plus Toremifene in the Treatment of Advanced First-line HR Positive and HER2 Negative Breast Cancer: a Multicenter, Single Arm, Exploratory Phase II Clinical Study
A Single-Center, Single-Arm, Open-Label Phase II Study of SHR-A1811 in Patients With Advanced Breast Cancer With Ultra-Low HER2 Expression
A Multicenter, Real-World Study Evaluating the Impact of Risk-Stratified Management of Inavolisib-Related Hyperglycemia on Patient Adherence
A Prospective Single-Arm Phase II Study of Pelvic External Beam Radiotherapy Followed by HDR Endorectal Brachytherapy Combined With a 3D-Printed Individualized Guide Template and Tungsten-Alloy Local Shielding for Organ Preservation in Inoperable Localized Rectal Cancer
Efficacy and Safety of Stereotactic Body Radiation Therapy for Spinal Metastases With Epidural Spinal Cord Compression (Bilsky Grade 1c-3): A Prospective, Multicenter, Single-Arm Phase II Study
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)